In Older Adults With Acute Coronary Syndrome, Age Alone Should Not Determine Treatment

Image Illustration by AI

FORMOSA NEWS - Bengkulu - A systematic review and meta-analysis by N. D. Putri, J. Endang, and Q. A. Dewi examined whether invasive treatment offers better overall outcomes than conservative management for acute coronary syndrome (ACS) patients aged 75 years and older. Published in the Indonesian Journal of Advanced Research (IJAR) in 2026, the review analyzed six randomized controlled trials involving more than 4,000 older patients from the United Kingdom, Spain, and Norway. The findings suggest that invasive treatment does not consistently outperform conservative care, highlighting the importance of considering frailty, other illnesses, functional ability, life expectancy, and patient preferences rather than chronological age alone.

Why Treating Older ACS Patients Is Challenging

Acute coronary syndrome includes serious heart conditions caused by reduced blood flow to the heart, including myocardial infarction and unstable angina. Managing ACS becomes more complicated in people aged 75 and above because older patients are more likely to have several health problems at the same time and may have reduced physiological reserves.

The review notes that coronary artery disease remains a major cause of illness and death among older adults worldwide. At advanced ages, conditions such as hypertension, diabetes, chronic kidney disease and frailty can affect both prognosis and the ability to tolerate invasive procedures.

Invasive treatment can involve coronary angiography followed, when appropriate, by procedures such as percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). These approaches can restore blood flow and may reduce some ischemic complications. However, they can also introduce risks such as bleeding, stroke and kidney injury related to contrast exposure.

This creates a difficult clinical question: should every older ACS patient automatically receive an invasive procedure, or should treatment be tailored to the individual's overall condition?

Researchers Compared Evidence From Six Clinical Trials

Putri, Endang and Dewi searched PubMed and the Cochrane Library in February 2026 for relevant studies published between 2016 and 2026. The review focused on patients aged 75 years and older who had ACS and compared invasive treatment with conservative or medication-based management.
The search initially identified 125 records. After screening and eligibility assessment, six studies were included in the qualitative and quantitative analysis. Together, they represented more than 4,000 older ACS patients. The studies came primarily from European countries, including the United Kingdom, Spain and Norway, and included patients with conditions such as NSTEMI and other non-ST-elevation ACS.

The researchers then combined the available results statistically to assess whether invasive treatment produced a consistent advantage over conservative management.

Invasive Treatment Did Not Consistently Reduce Overall Risk

The central finding was that invasive treatment did not show a statistically significant overall advantage compared with conservative management.

The pooled analysis produced a Hedges' g of −1.04, with a 95% confidence interval from −3.12 to 1.04. The researchers also found substantial variation between studies, with an I² value of 99%. This means the results differed considerably across the studies and should therefore be interpreted cautiously.

The review found that invasive treatment tended to reduce nonfatal myocardial infarction and the need for repeat revascularization. However, these potential benefits did not translate consistently into lower overall mortality or better major cardiovascular outcomes across the elderly population. At the same time, bleeding complications tended to be more common in patients receiving invasive treatment.

Key findings include:

  • No consistent overall mortality benefit from invasive treatment compared with conservative management.
  • A possible reduction in nonfatal heart attacks among patients receiving invasive treatment.
  • A possible reduction in repeat revascularization procedures.
  • Higher concern about complications, particularly bleeding, in invasive-treatment groups.
  • Large differences between studies, indicating that older ACS patients cannot be treated as a single uniform group.

Frailty May Matter More Than Age

One of the most important messages from the review is that chronological age alone is an incomplete measure of treatment risk.

The researchers highlight frailty as a major factor influencing whether an older patient is likely to benefit from invasive treatment. Frail patients may have less physiological reserve and a higher risk of complications. In the MOSCA-FRAIL study discussed in the review, invasive management did not improve the number of days patients remained alive and out of hospital or other cardiovascular outcomes. Conservative management produced comparable or potentially better short-term quality-of-life results in frail patients.

At the same time, the review does not suggest that invasive treatment should be avoided in all patients aged 75 and above. Some studies reported meaningful long-term benefits. The After Eighty study, for example, found reductions in myocardial infarction, urgent revascularization, stroke and mortality among selected patients aged 80 years and older.

This contrast is central to the researchers' “beyond chronological age” concept.

Treatment Should Be Individualized

According to Putri, Endang and Dewi, clinicians should consider several factors before deciding between invasive and conservative treatment.

These include the patient's degree of frailty, other medical conditions, cognitive and functional status, quality of life, expected life expectancy and personal treatment preferences. Patients who remain functionally independent and have sufficient life expectancy may potentially gain more from invasive intervention, while highly frail patients may face greater procedural risks.

The authors therefore support individualized, risk-based decision-making rather than a one-size-fits-all approach. They also point to the potential value of validated cardiovascular risk scores, systematic frailty assessments and multidisciplinary discussions when managing older ACS patients.

Implications for Health Care

The findings could influence how hospitals and clinicians approach cardiovascular treatment in an aging population. Rather than using an age threshold as an automatic trigger for or against invasive treatment, doctors may need to evaluate the patient's biological and functional condition in greater detail.

For patients and families, the findings also reinforce the importance of discussing expected benefits, possible complications and quality-of-life priorities before major cardiovascular procedures.

The researchers recommend future studies that incorporate frailty more systematically, examine long-term quality-of-life outcomes and develop risk-prediction models specifically designed for older patients.

Author Profile

N. D. Putri is a physician affiliated with the Medical and Health Division of the Bengkulu Regional Police and served as the corresponding author. J. Endang is a cardiologist based in Bengkulu, while Q. A. Dewi is affiliated with Curup Community Health Center. Their work focuses on cardiovascular management in older patients, particularly the balance between invasive and conservative strategies for acute coronary syndrome.

Research Source

Article: “Beyond Chronological Age: Balancing Risk and Benefit of Invasive Versus Conservative Strategies in Acute Coronary Syndrome Patients Aged ≥75 Years. A Systematic Review and Meta-Analysis”
Authors: N. D. Putri, J. Endang, Q. A. Dewi
Journal: Indonesian Journal of Advanced Research (IJAR)
Volume: 5, No. 8
Year: 2026
Pages: 1573–1586

Posting Komentar

0 Komentar